Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lori M Millner

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinics in Laboratory Medicine|August 13, 2016
The Future of Precision Medicine in OncologyLori M Millner, Lindsay N Strotman
Expert Opinion on Drug Metabolism & Toxicology|October 23, 2020
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused reviewDavid W Hein, Lori M Millner
Annals of Clinical and Laboratory Science|July 26, 2013
Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypesLori M Millner, Mark W Linder, Roland Valdes
Molecular Diagnosis & Therapy|June 22, 2016
Liquid Biopsies in Oncology and the Current Regulatory LandscapeLindsay N Strotman, Lori M Millner, Roland Valdes, et al.
Carcinogenesis|November 26, 2009
Relationship between N-acetyltransferase 2 single-nucleotide polymorphisms and phenotypeDavid W Hein, Lori M Millner, Carmine S Leggett, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 20, 2011
Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependentLori M Millner, Mark A Doll, Jian Cai, et al.
Molecular Carcinogenesis|August 13, 2011
NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenylLori M Millner, Mark A Doll, Jian Cai, et al.
Carcinogenesis|November 25, 2011
Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA constructLori M Millner, Mark A Doll, Marcus W Stepp, et al.
Mutation Research|August 18, 2009
Differences between human slow N-acetyltransferase 2 alleles in levels of 4-aminobiphenyl-induced DNA adducts and mutationsJean Bendaly, Mark A Doll, Lori M Millner, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinics in Laboratory Medicine|August 13, 2016
The Future of Precision Medicine in OncologyLori M Millner, Lindsay N Strotman
Expert Opinion on Drug Metabolism & Toxicology|October 23, 2020
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused reviewDavid W Hein, Lori M Millner
Annals of Clinical and Laboratory Science|July 26, 2013
Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypesLori M Millner, Mark W Linder, Roland Valdes
Molecular Diagnosis & Therapy|June 22, 2016
Liquid Biopsies in Oncology and the Current Regulatory LandscapeLindsay N Strotman, Lori M Millner, Roland Valdes, et al.
Carcinogenesis|November 26, 2009
Relationship between N-acetyltransferase 2 single-nucleotide polymorphisms and phenotypeDavid W Hein, Lori M Millner, Carmine S Leggett, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 20, 2011
Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependentLori M Millner, Mark A Doll, Jian Cai, et al.
Molecular Carcinogenesis|August 13, 2011
NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenylLori M Millner, Mark A Doll, Jian Cai, et al.
Carcinogenesis|November 25, 2011
Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA constructLori M Millner, Mark A Doll, Marcus W Stepp, et al.
Mutation Research|August 18, 2009
Differences between human slow N-acetyltransferase 2 alleles in levels of 4-aminobiphenyl-induced DNA adducts and mutationsJean Bendaly, Mark A Doll, Lori M Millner, et al.
Pageof 1